The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3
Open accessAbstract
Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase that is particularly abundant in the CNS. Dysregulation of GSK-3 activity is believed to play a key role in the pathogenesis of CNS chronic disorders such as Alzheimer's disease (AD), bipolar disorder, and Huntington's disease, and of metabolic disorders such as type II diabetes. Accordingly, GSK-3 inhibitors have been postulated as therapeutic tools for these diseases. Interestingly, pathophysiological and pharmacological regulation of GSK-3 is affected by an amplification mechanism that applies both to inhibition and activation. The possibility therefore exists that sustained inhibition or activation might persist after cessation of the initial trigger. Regarding AD, GSK-3 has been shown to accumulate in pretangle neurons. Furthermore, GSK-3 phosphorylates tau in most serine and threonine residues hyperphosphorylated in PHF (paired helical filament)-tau and GSK-3 activity contributes both to β-amyloid production and to β-amyloid-mediated neuronal death. In good agreement, mice with conditional overexpression of GSK-3 in forebrain neurons (Tet/GSK-3β mice) recapitulate aspects of AD neuropathology such as tau hyperphosphorylation, apoptotic neuronal death, and reactive astrocytosis as well as spatial learning deficit. Here, we exploit the conditional system used to generate Tet/GSK-3β mice to explore whether the biochemical, histopathological, and behavioral consequences of increased GSK-3 activity are susceptible to revert after restoration of normal GSK-3 levels. Here, we show that transgene shutdown in symptomatic mice leads to normal GSK-3 activity, normal phospho-tau levels, diminished neuronal death, and suppression of the cognitive deficit, thus further supporting the potential of GSK-3 inhibitors for AD therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,417
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Microtubule Assembly in the Absence of Added Nucleotides
Shelanski, M. L., Gaskin, F., & Cantor, C. R. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.3.765 · Cited by 2,053
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Self-citationRole of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005
Self-citationPhosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901
Lucas, J. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 900
Self-citationGSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Ennaceur, A., Neave, N., & Aggleton, J. P. (1997) · Experimental Brain Research · doi:10.1007/pl00005603 · Cited by 670
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608
β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding
Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90232-5 · Cited by 595
Mitogen inactivation of glycogen synthase kinase-3 β in intact cells via serine 9 phosphorylation
Stambolic, V, & Woodgett, J. R. (1994) · Biochemical Journal · doi:10.1042/bj3030701 · Cited by 581
Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau.
Greenberg, S. G., Davies, P., Schein, J. D., & Binder, L. I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48531-6 · Cited by 543
Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis
Zhang, Z., Hartmann, H., Minh Do, V., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., van de Wetering, M., Clevers, H., Saftig, P., et al. (1998) · Nature · doi:10.1038/27208 · Cited by 517
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
Jope, R. S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00206-2 · Cited by 500
Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404
Otvos, L., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., & Lee, V. M. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490390607 · Cited by 488
Biernat, J., Mandelkow, E. M., Schröter, C., Lichtenberg‐Kraag, B., Steiner, B., Berling, B., Meyer, H., Mercken, M., Vandermeeren, A., & Goedert, M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05204.x · Cited by 484
Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3
Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25326 · Cited by 469
Lovestone, S., Reynolds, C. H., Latimer, D., Davis, D. R., Anderton, B. H., Gallo, J.-M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S., et al. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00246-3 · Cited by 469
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 455
Glycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435
Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau
Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9637 · Cited by 409
Glycogen synthase kinase 3: a drug target for CNS therapies
Bhat, R. V., Budd Haeberlein, S. L., & Avila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 408
Self-citationGlycogen synthase kinase 3: an emerging therapeutic target
Eldar-Finkelman, H. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02266-3 · Cited by 407
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.
Takashima, A., Noguchi, K., Sato, K., Hoshino, T., & Imahori, K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7789 · Cited by 381
Cross, D. A. E., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D., & Reith, A. D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00251.x · Cited by 377
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Self-citationMercken, M., Vandermeeren, M., Lübke, U., Six, J., Boons, J., Van de Voorde, A., Martin, J.-J., & Gheuens, J. (1992) · Acta Neuropathologica · doi:10.1007/bf00227819 · Cited by 355
Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons
Muñoz-Montaño, J. R., Moreno, F. J., Avila, J., & Dı́az-Nido, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00688-1 · Cited by 322
Self-citationSpittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006219200 · Cited by 316
Lithium protects cultured neurons against β‐amyloid‐induced neurodegeneration
Alvarez, G., Muñoz-Montaño, J. R., Satrústegui, J., Avila, J., Bogónez, E., & Dı́az-Nido, J. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00685-7 · Cited by 270
Self-citationTakashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., & Imahori, K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12257-5 · Cited by 260 · cited 1×
“…from its precursor APP (amyloid precursor protein) (Sun et al., 2002; Phiel et al., 2003; Ryder et al., 2003), and A-mediated toxicity to cultured neurons depends on increased GSK-3 activity (Takashima et al., 1993, 1996; Busciglio et al., 1995; Ferreira et al., 1997; Alvarez et al., 1999).”
Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models
Price, D. L., Sisodia, S. S., & Borchelt, D. R. (1998) · Science · doi:10.1126/science.282.5391.1079 · Cited by 259
Huntington's disease: the challenge for cell biologists
Tobin, A. J., & Signer, E. R. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01853-5 · Cited by 229
Novak, M., Jakes, R., Edwards, P. C., Milstein, C., & Wischik, C. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5837 · Cited by 216
Lovestone, S., Hartley, C. L., Pearce, J., & Anderton, B. H. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00126-1 · Cited by 201
Wang, J.-Z., Wu, Q., Smith, A., Grundke-Iqbal, I., & Iqbal, K. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01090-4 · Cited by 197
Carmichael, J., Sugars, K. L., Bao, Y. P., & Rubinsztein, D. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204861200 · Cited by 195
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model
Pérez, M., Hernández, F., Lim, F., Díaz-Nido, J., & Avila, J. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5405 · Cited by 180
Self-citationFerreira, A., Lu, Q., Orecchio, L., & Kosik, K. S. (1997) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1997.0615 · Cited by 178
Buée‐Scherrer, V., Condamines, O., Mourton-Gilles, C., Jakes, R., Goedert, M., Pau, B., & Delacourte, A. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(96)00003-4 · Cited by 170
Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100
Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J.-M., Yamaguchi, H., & Takashima, A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02583-6 · Cited by 161
Divergent roles of GSK3 and CDK5 in APP processing
Ryder, J. W., Yuan, S., Liu, F., Li, B., Zhou, Y., & Ni, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.014 · Cited by 144
Role of glycogen synthase kinase-3 in cancer: Regulation by Wnts and other signaling pathways
Manoukian, A. S., & Woodgett, J. R. (2002) · Advances in cancer research · doi:10.1016/s0065-230x(02)84007-6 · Cited by 143
GSK-3 and the neurodevelopmental hypothesis of schizophrenia
Kozlovsky, N., Belmaker, R. H., & Agam, G. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00131-6 · Cited by 135
Woolley, M. L., Marsden, C. A., Sleight, A. J., & Fone, K. C. F. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1552-5 · Cited by 131
Tau protein I is essential for amyloid β-protein iduced neurotoxicity
Takashima, A. (1993) · Medical Entomology and Zoology · Cited by 125
Engel, T., Lucas, J. J., Gómez‐Ramos, P., Morán, M. A., Ávila, J., & Hernández, F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.010 · Cited by 124
Self-citationFunctional studies of Alzheimer's disease tau protein
Lu, Q., & Jg, W. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-02-00508.1993 · Cited by 105
Szatmari, E. M., Habas, A., Yang, P., Zheng, J., Hagg, T., & Hetman, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502699200 · Cited by 91
Díaz-Hernández, M., Torres-Peraza, J. F., Salvatori-Abarca, A., Morán, M. A., Gómez‐Ramos, P., Alberch, J., & Lucas, J. J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3183-05.2005 · Cited by 90
Self-citationImmunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology
Shiurba, R., Ishiguro, K., Takahashi, M., Sato, K., Spooner, E. T., Mercken, M. H., Yoshida, R. Y., Wheelock, T. R., Yanagawa, H., Imahori, K., et al. (1996) · Brain Research · doi:10.1016/0006-8993(96)00717-2 · Cited by 74
Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway
Berger, Z., Ttofi, E. K., Michel, C. H., Pasco, M. Y., Tenant, S., Rubinsztein, D. C., & O’Kane, C. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi331 · Cited by 71
Scheele, R. B., & Borisy, G. G. (1976) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(76)91100-1 · Cited by 54
Maurage, C.-A., Sergeant, N., Ruchoux, M.-M., Hauw, J.-J., & Delacourte, A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0608-7 · Cited by 51
Moreno, F., Mu�oz-Monta�o, J. R., & Ávila, J. (1996) · Molecular and Cellular Biochemistry · doi:10.1007/bf00229744 · Cited by 33
Binding specificity of monoclonal antibody AD2: influence of the phosphorylation state of tau
Torreilles, F., Roquet, F., Granier, C., Pau, B., & Mourton-Gilles, C. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00073-5 · Cited by 10
Cited by
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Halagappa, V. K. M., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R. G., LaFerla, F. M., & Mattson, M. P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.019 · Cited by 580
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
Metadata
- Authors
- Engel, T., Hernández, F., Avila, J., & Lucas, J. J.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-05-10
- Volume
- 26
- Issue
- 19
- Pages
- 5083-5090
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2150802333
- Cited by
- 260
- References
- 65
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.